@ BioWorld, Islet Sciences' subsidiary receives $2.1 million in grant funding - $ISLT

@ BioWorld, Islet Sciences' subsidiary receives $2.1 million in grant funding - $ISLT

Islet Sciences, Inc. (OTCBB: ISLT) is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes. The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immuno-protection (microencapsulation) of islet cells. Islet Sciences’ mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace.

Islet Sciences was mentioned in the "Other News to Note" section of BioWorld Today, the daily biopharmaceutical news source:

"Islet Sciences Inc., of New York, said subsidiary DiaKine Therapeutics Inc. received a $2. 1 million in grant funding, comprising about $1 .83 million from the National Institutes of Health and $250,000 from the Iacocca Foundation to support its work in diabetes. Islet acquired DiaKine in a stock deal last month."

About BioWorld

BioWorld Today delivers actionable intelligence on the biotech science that drives the business, which funds the means to heal disease. With writers and editors stationed around the globe, BioWorld Today reports the breaking news -- and provides key perspective -- on hundreds of medicines in development, the companies behind those therapeutic candidates, the business development transactions that evolve the market, and the regulatory hurdles that both challenge and guard the process. Read more at BioWorld.com.